iwMPN 2025 highlights: novel approaches to the upfront management of myelofibrosis, cardiovascular health in MPNs, & more

In this week’s VJHemOnc podcast, we’ll be sharing highlights in myeloproliferative neoplasms (MPNs) from the recent 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025. First, you will hear a roundtable discussion, in which Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Donal McLornan, MB, BCh, MRCP, PhD, FRCPath, University College London Hospitals, London, UK, and Haifa Kathrin Al-Ali, MD, Krukenberg Cancer Center, Halle, Germany, provide insight into novel approaches for the upfront management of myelofibrosis. The experts discuss the need to define a suboptimal response to therapy and outline some of the agents being investigated for myelofibrosis in the frontline setting.

Following this, Alexander Lyon, MA, BM, BCh, PhD, FRCP, FHFA, Royal Brompton Hospital, London, UK, discusses cardiovascular health in patients with MPNs, and Adrián Mosquera Orgueira, MD, PhD, Santiago Clinic Hospital CHUS, Santiago, Spain, provides insight into the application of artificial intelligence (AI) in the MDS/MPN setting.